Increased μ-opioid receptor expression in metastatic lung cancer

British Journal of Anaesthesia

Volumn 113, Issue SUPPL. 1, 2014, Pages

  Singleton, P A ^a,b   Mirzapoiazova, T ^a   Hasina, R ^c   Salgia, R ^c   Moss, J ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

lung cancer; metastasis; methylnaltrexone; MOR; opioid receptor

Indexed keywords

MU OPIATE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; METASTASIS; METASTATIC LUNG CANCER; PATHOLOGIST; PRIORITY JOURNAL; TUMOR INVASION; VERY ELDERLY;

LUNG CANCER; METASTASIS; METHYLNALTREXONE; MOR; Μ-OPIOID RECEPTOR;

AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RECEPTORS, OPIOID, MU;

EID: 84905045924     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu165     Document Type: Article

References (39)

1. Bovill JG. Surgery for cancer: does anesthesia matter? Anesth Analg 2010; 110: 1524-6
2. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105: 106-15
3. Yeager MP, Rosenkranz KM. Cancer recurrence after surgery: a role for regional anesthesia? Reg Anesth Pain Med 2010; 35: 483-4
4. Lennon FE, Moss J, Singleton PA. The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 2012; 116: 940-5
5. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008; 109: 180-7
6. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105: 660-4
7. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 2008; 107: 325-32
8. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. Br Med J 2011; 342: d1491
9. Tavare AN, Perry NJ, Benzonana LL, Takata M, Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer 2012; 130: 1237-50
10. Afsharimani B, Cabot PJ, Parat MO. Morphine use in cancer surgery. Front Pharmacol 2011; 2: 46
11. Afsharimani B, Cabot P, Parat MO. Morphine and tumorgrowth and metastasis. Cancer Metastasis Rev 2011; 30: 225-38
12. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 2012; 116: 857-67
13. Mathew B, Lennon FE, Siegler J, et al. The novel role of the muopioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112: 558-67
14. Spiro SG, Tanner NT, Silvestri GA, et al. Lung cancer: progressin diagnosis, staging and therapy. Respirology 2010; 15: 44-50
15. Stinchcombe TE, Bogart J, Veeramachaneni NK, Kratzke R, Govindan R. Annual review of advances in non-small cell lung cancer research: a report for the year 2010. J Thorac Oncol 2011; 6: 1443-50
16. Carlson JJ. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 409-16
17. Choi EJ, Ryu YK, Kim SY, et al. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res 2010; 8: 1027-36
18. Ganjoo KN, Wakelee H. Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics 2007; 1: 335-46
19. Gridelli C, Morabito A, Gebbia V, et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: the cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomizedphaseIItrials. Lung Cancer 2010; 67: 86-92
20. De Greve J, Decoster L, Van Meerbeek J, Vermeij J, Teugels E, Schallier D. [Targeted therapies in the treatment of non-small cell lung cancer]. Bull Cancer 2008; 95: 358-64
21. Ng R, Loreto M, Lee R, Leighl NB. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 2008; 61: 262-5
22. Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, Govindan R. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the Clini-calTrials. gov website. J Thorac Oncol 2010; 5: 1116-9
23. Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 2011; 113: 1353-64
24. Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013; 119: 4103-10
25. Kawada I, Hasina R, Lennon FE, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther 2013; 14: 679-91
26. Faoro L, Singleton PA, Cervantes GM, et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 2010; 285: 18575-85
27. Cembrowski GS, Westgard JO, Conover WJ, Toren EC Jr. Statistical analysis of method comparison data. Testing normality. Am J Clin Pathol 1979; 72: 21-6
28. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angio-genesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62: 4491-8
29. Singleton PA, Mambetsariev N, Lennon FE, et al. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenesis Res 2010; 2: 5
30. Singleton PA, Moss J. Effect of perioperative opioids on cancer recur-rence: a hypothesis. Future Oncol 2010; 6: 1237-42
31. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 2006; 72: 3-11
32. Singleton PA, Garcia JG, Moss J. Synergistic effects of methylnaltrex-one with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 2008; 7: 1669-1679
33. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA. mu-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 2012; 116: 896-902
34. Wang S, Li Y, Liu XD, Zhao CX, Yang KQ. Polymorphism of A118G in mu-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol 2013; 18: 666-9
35. Rastogi B, Gupta K, Rastogi A, Gupta PK, Singhal AB, Singh I. Hemi-arthroplasty in high risk elderly patient under epidural anesthesia with 0. 75% ropivacaine-fentanyl versus 0. 5% bupivacaine-fentanyl: clinical trial. Saudi J Anaesth 2013; 7: 142-5
36. Donahue RN, McLaughlin PJ, Zagon IS. Low-dosenaltrex one targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence fromatissue culture model. Exp Biol Med (Maywood) 2011; 236: 1036-50
37. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke WH, Duthey B. Endogenous mu-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 2011; 20: 24-8
38. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrex-one: role of mOP-R and S1P3 transactivation. Am J Resp Cell Mol Biol 2007; 37: 222-31
39. Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition (EMT) in human lung cancer. PLoS One 2014; 9: e91577